Adult Dosing
Urinary tract infections
- 400 mg PO q12 hrs x 3-21 days, depending on severity of infection
Uncomplicated urethral and cervical gonorrhea
Prostatitis
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
Renal Dose Adjustment (Based on CrCl)
- 30 mL/min or less: 400 mg once daily
Hepatic Dose Adjustment
- Hepatic impairment: Dose adjustments not defined
See Supplemental Patient Information
- Norfloxacin may increase risk of tendinitis and tendon rupture in all ages. Discontinue treatment if pain or inflammation in a tendon occurs [US Black Box Warning]
- Safety and effectiveness of norfloxacin in pregnant and lactating women have not been established
- Therapy may exacerbate muscle weakness in persons with myasthenia gravis. Avoid use in patients with known history of myasthenia gravis
- Serious and occasionally fatal hypersensitivity and/or anaphylactic reactions have been reported in patients receiving therapy with fluoroquinolones, including norfloxacin
- Prolongation of the QT interval and isolated cases of torsade de pointes have been reported
- Avoid use in patients with known QT prolongation, those with hypokalemia, and with other drugs that prolong the QT interval
- Clostridium difficile-associated diarrhea (CDAD) has been reported with use of the drug and may range in severity from mild diarrhea to fatal colitis.
- An increased incidence of musculoskeletal disorders (arthralgia, arthritis, tendonopathy, and gait abnormality) compared to controls has been observed in pediatric patients treated with this drug. It is not drug of first choice in children due to increased adverse reactions related to joints and surrounding tissue. Do not use in patients < 18 yrs of age, except for listed indications
- Seizures, increased ICP and toxic psychosis have been reported in patients taking norfloxacin. May also cause nervousness, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression
- Moderate to severe photosensitivity reactions have occurred with some fluoroquinolones. Avoid excessive sunlight exposure
- Monitor creatinine at baseline, then periodically if elderly or prolonged therapy
- Monitor CBC, LFTs if prolonged therapy
- Cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have occurred in patients
- Discontinue therapy if the patient experiences symptoms of neuropathy including pain, burning, tingling, numbness, and/or weakness or other alterations of sensation including light touch, pain, temperature, position sense, and vibratory sensation in order to prevent the development of an irreversible condition
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Kidney, heart or lung transplant
- QT prolongation
- Seizure disorder
- CNS disorder
- Dehydration
- Diabetes mellitus
- Elderly patients (>60 yrs)
- Proarrhythmic condition
- G6PD deficiency
- Proarrhythmic condition
Supplemental Patient Information
- Use sunscreen to reduce phototoxicity
- Report any CNS effect to health professional. Avoid activities requiring coordination until effects are realized
- Should not take drug with dairy products or with in 2 hr and 6 hr after magnesium or aluminum antacids
- Inform patient about tendon rupture risk
Pregnancy Category:C
Breastfeeding: Fluoroquinolones have not been used in infants because of concern about adverse effects on the infants developing joints. Avoiding breastfeeding for 3-4 hrs after a dose can decrease infant exposure; however, other agents might be preferred. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT). This drug is compatible and considered safe with breastfeeding based upon data from AAP Policy Guidelines (available at http://aappolicy.aappublications.org/cgi/content/full/pediatrics;108/3/776 last accessed 25 April 2011). Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
US Trade Name(s)
US Availability
Noroxin
Canadian Trade Name(s)
Canadian Availability
norfloxacin (generic)
UK Trade Name(s)
UK Availability
Utinor
Australian Trade Name(s)
- Norflohexal
- Noroxin
- Nufoxib
- Roxin
Australian Availability
norfloxacin (generic)
Norflohexal, Noroxin, Nufoxib, Roxin
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Noroxin 400 MG TABS [Bottle] (MERCK SHARP & DOHME)
20 mg = $85.51
60 mg = $235.14
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Noroxin 400 MG Oral Tablet
Ingredient(s): Norfloxacin
Imprint: 705
Color(s): White
Shape: Oval
Size (mm): 17.00
Score: 1
Inactive Ingredient(s): cellulose / croscarmellose sodium / hydroxypropyl cellulose / hydroxypropyl methylcellulose / magnesium stearate / titanium dioxide
Drug Label Author:
Merck & Co., Inc.
DEA Schedule:
Non-Scheduled
